porozendoОстеопороз и остеопатииOsteoporosis and Bone Diseases2072-26802311-0716Endocrinology Research Centre10.14341/osteo12943porozendo-12943Research ArticleНаучный обзорReviewКостная патология при хронической болезни почекBone pathology in chronic kidney diseasehttps://orcid.org/0000-0001-5059-3287КарловичН. В.KarlovichN. V.

 Карлович Наталия Викторовна, докторант, к.м.н., доцент кафедры эндокринологии 

220040, г. Минск, пр-т Независимости, 64 

Natalia V. Karlovich, MD, PhD, Assistant Professor

220040, Minsk, Nezavisimosti ave, 64

natkarlovich@gmail.comhttps://orcid.org/0000-0002-5040-3460МохортТ. В.MokhortT. V.

Мохорт Татьяна Вячеславовна, профессор, д.м.н.

Минск

Tatiana V. Mokhort, MD, PhD, Professor

Minsk

tatsianamokhort@gmail.comhttps://orcid.org/0000-0003-2480-1278СазоноваЕ. Г.SazonavaA. G. 

Сазонова Елена Геннадьевна, к.м.н.

Минск

Alena G. Sazonava, MD, PhD

Minsk

trofi_elena@mail.ruУчреждение образования «Белорусский государственный медицинский университет»БеларусьBelarusian State Medical UniversityBelarusГосударственное учреждение «Республиканский центр медицинской реабилитации и бальнеолечения»БеларусьRepublican Center of Medical Rehabilitation and BalneotherapyBelarus2022090820222512938Copyright © Карлович Н.В., Мохорт Т.В., Сазонова Е.Г., 20222022Карлович Н.В., Мохорт Т.В., Сазонова Е.Г.Karlovich N.V., Mokhort T.V., Sazonava A.G.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.osteo-endojournals.ru/jour/article/view/12943

В статье представлены современные данные о минерально-костных нарушениях у пациентов с различными стадиями хронической болезни почек. Отражены особенности поражения костей у данной категории лиц, которые включают нарушение секреции паратиреоидного гормона и фосфорно-кальциевого метаболизма, специфическую остеопатию и внескелетную кальцификацию, указано на взаимосвязь костной патологии и сердечно-сосудистых осложнений. Обсуждается роль диагностических инструментов (опросник FRAX, костная остеоденситометрия, биохимические параметры и новые биологические маркеры), определены подходы к интерпретации результатов исследований. Описаны как общепопуляционные, так и специфические факторы риска снижения прочности кости и возникновения остеопоротических переломов при хронической болезни почек.

The article presents current data on mineral and bone disorders in patients with various stages of chronic kidney disease. The key points of bone lesions pathology are reflected, which include impaired secretion of parathyroid hormone and phosphorus-calcium metabolism, specific osteopathy and extraskeletal calcification, the relationship between bone pathology and cardiovascular complications is indicated. The role of diagnostic tools (FRAX questionnaire, bone densitometry, biochemical parameters and new biological markers) is discussed, approaches to the interpretation of research results are defined. Both general population and specific risk factors for bone strength decrease and occurrence of osteoporotic fractures pathology in chronic kidney disease are described.

хроническая болезнь почеквторичный гиперпаратиреозмаркеры костного метаболизмаостеопорозкостная денситометриясhronic kidney diseasesecondary hyperparathyroidismmarkers of bone metabolismosteoporosisbone densitometryReferencesKDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. Suppl. 2013;3:S1-S150.KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. Suppl. 2013;3:S1-S150.Bello AK, Levin A, Lunney M, et al. Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional survey. BMJ. 2019;367: l5873. doi: https://doi.org/10.1136/bmj.l5873Bello AK, Levin A, Lunney M, et al. Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional survey. BMJ. 2019;367: l5873. doi: https://doi.org/10.1136/bmj.l5873Moe S, Drüeke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69(11):1945-1953. doi: https://doi.org/10.1038/sj.ki.5000414Moe S, Drüeke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69(11):1945-1953. doi: https://doi.org/10.1038/sj.ki.5000414Moe SM. Renal Osteodystrophy or Kidney-Induced Osteoporosis? Curr Osteoporos Rep. 2017;15(3):194-197. doi: https://doi.org/10.1007/s11914-017-0364-1Moe SM. Renal Osteodystrophy or Kidney-Induced Osteoporosis? Curr Osteoporos Rep. 2017;15(3):194-197. doi: https://doi.org/10.1007/s11914-017-0364-1Sprague SM, Bellorin-Font E, Jorgetti V, et al. Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis. Am J Kidney Dis. 2016;67(4):559-566. doi: https://doi.org/10.1053/j.ajkd.2015.06.023Sprague SM, Bellorin-Font E, Jorgetti V, et al. Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis. Am J Kidney Dis. 2016;67(4):559-566. doi: https://doi.org/10.1053/j.ajkd.2015.06.023Slatopolsky E, Gonzalez E, Martin K. Pathogenesis and treatment of renal osteodystrophy. Blood Purif. 2003;21(4-5):318-326. doi: https://doi.org/10.1159/000072552Slatopolsky E, Gonzalez E, Martin K. Pathogenesis and treatment of renal osteodystrophy. Blood Purif. 2003;21(4-5):318-326. doi: https://doi.org/10.1159/000072552Spasovski GB. Bone biopsy as a diagnostic tool in the assessment of renal osteodystrophy. Int J Artif Organs. 2004;27(11):918-923. doi: https://doi.org/10.1177/039139880402701103Spasovski GB. Bone biopsy as a diagnostic tool in the assessment of renal osteodystrophy. Int J Artif Organs. 2004;27(11):918-923. doi: https://doi.org/10.1177/039139880402701103Trueba D, Sawaya BP, Mawad H, Malluche HH. Bone biopsy: indications, techniques, and complications. Semin Dial. 2003;16(4):341-345. doi: https://doi.org/10.1046/j.1525-139x.2003.160631.xTrueba D, Sawaya BP, Mawad H, Malluche HH. Bone biopsy: indications, techniques, and complications. Semin Dial. 2003;16(4):341-345. doi: https://doi.org/10.1046/j.1525-139x.2003.160631.xCosman F, de Beur SJ, LeBoff MS, et al. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int. 2014;25(10):2359-2381. doi: https://doi.org/10.1007/s00198-014-2794-2Cosman F, de Beur SJ, LeBoff MS, et al. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int. 2014;25(10):2359-2381. doi: https://doi.org/10.1007/s00198-014-2794-2Bellasi A, Raggi P. Bone metabolism and cardiovascular disease: An overlooked association? Atherosclerosis. 2021;335:87-88. doi: https://doi.org/10.1016/j.atherosclerosis.2021.09.009Bellasi A, Raggi P. Bone metabolism and cardiovascular disease: An overlooked association? Atherosclerosis. 2021;335:87-88. doi: https://doi.org/10.1016/j.atherosclerosis.2021.09.009Cannata-Andía JB, Martín-Carro B, Martín-Vírgala J, et al. Chronic Kidney Disease-Mineral and Bone Disorders: Pathogenesis and Management. Calcif Tissue Int. 2021;108 (4):410-422. doi: https://doi.org/10.1007/s00223-020-00777-1Cannata-Andía JB, Martín-Carro B, Martín-Vírgala J, et al. Chronic Kidney Disease-Mineral and Bone Disorders: Pathogenesis and Management. Calcif Tissue Int. 2021;108 (4):410-422. doi: https://doi.org/10.1007/s00223-020-00777-1Horl WH. The clinical consequences of secondary hyperparathyroidism: focus on clinical outcomes. Nephrol Dial Transplant. 2004;19(5):v2-v8. doi: https://doi.org/10.1093/ndt/gfh1049Horl WH. The clinical consequences of secondary hyperparathyroidism: focus on clinical outcomes. Nephrol Dial Transplant. 2004;19(5):v2-v8. doi: https://doi.org/10.1093/ndt/gfh1049Bousson V, Bergot C, Sutter B, et al. Trabecular bone score (TBS): available knowledge, clinical relevance, and future prospects. Osteoporos Int. 2012;23(5):1489-1501. doi: https://doi.org/10.1007/s00198-011-1824-6Bousson V, Bergot C, Sutter B, et al. Trabecular bone score (TBS): available knowledge, clinical relevance, and future prospects. Osteoporos Int. 2012;23(5):1489-1501. doi: https://doi.org/10.1007/s00198-011-1824-6Beaubrun AC, Kilpatrick RD, Freburger JK, et al. Temporal Trends in Fracture Rates and Postdischarge Outcomes among Hemodialysis Patients. J Am Soc Nephrol. 2013;24(9):1461-1469. doi: https://doi.org/10.1681/ASN.2012090916Beaubrun AC, Kilpatrick RD, Freburger JK, et al. Temporal Trends in Fracture Rates and Postdischarge Outcomes among Hemodialysis Patients. J Am Soc Nephrol. 2013;24(9):1461-1469. doi: https://doi.org/10.1681/ASN.2012090916Chandran M, Wong J. Secondary and tertiary hyperparathyroidism in chronic kidney disease: An endocrine and renal perspective. Indian J Endocrinol Metab. 2019;23(4):391-399. doi: https://doi.org/10.4103/ijem.IJEM_292_19Chandran M, Wong J. Secondary and tertiary hyperparathyroidism in chronic kidney disease: An endocrine and renal perspective. Indian J Endocrinol Metab. 2019;23(4):391-399. doi: https://doi.org/10.4103/ijem.IJEM_292_19Wagner J, Jhaveri KD, Rosen L, et al. Increased bone fractures among elderly United States hemodialysis patients. Nephrol Dial Transplant. 2014;29(1):146-151. doi: https://doi.org/10.1093/ndt/gft352Wagner J, Jhaveri KD, Rosen L, et al. Increased bone fractures among elderly United States hemodialysis patients. Nephrol Dial Transplant. 2014;29(1):146-151. doi: https://doi.org/10.1093/ndt/gft352Tentori F, Wang M, Bieber BA, et al. Recent Changes in Therapeutic Approaches and Association with Outcomes among Patients with Secondary Hyperparathyroidism on Chronic Hemodialysis: The DOPPS Study. Clin J Am Soc Nephrol. 2015;10(1):98-109. doi: https://doi.org/10.2215/CJN.12941213Tentori F, Wang M, Bieber BA, et al. Recent Changes in Therapeutic Approaches and Association with Outcomes among Patients with Secondary Hyperparathyroidism on Chronic Hemodialysis: The DOPPS Study. Clin J Am Soc Nephrol. 2015;10(1):98-109. doi: https://doi.org/10.2215/CJN.12941213Rivet J, Lebbé C, Urena P, et al. Cutaneous Calcification in Patients With End-Stage Renal Disease. Arch Dermatol. 2006;142(7):900-906. doi: https://doi.org/10.1001/archderm.142.7.900Rivet J, Lebbé C, Urena P, et al. Cutaneous Calcification in Patients With End-Stage Renal Disease. Arch Dermatol. 2006;142(7):900-906. doi: https://doi.org/10.1001/archderm.142.7.900Moe SM, Drüeke T, Lameire N, Eknoyan G. Chronic Kidney Disease–Mineral-Bone Disorder: A New Paradigm. Adv Chronic Kidney Dis. 2007;14(1):3-12. doi: https://doi.org/10.1053/j.ackd.2006.10.005Moe SM, Drüeke T, Lameire N, Eknoyan G. Chronic Kidney Disease–Mineral-Bone Disorder: A New Paradigm. Adv Chronic Kidney Dis. 2007;14(1):3-12. doi: https://doi.org/10.1053/j.ackd.2006.10.005Weisinger JR, Bellorin-Font E. Outcomes associated with hypogonadism in women with chronic kidney disease. Adv Chronic Kidney Dis. 2004;11(4):361-370. doi: https://doi.org/10.1053/j.ackd.2004.07.009Weisinger JR, Bellorin-Font E. Outcomes associated with hypogonadism in women with chronic kidney disease. Adv Chronic Kidney Dis. 2004;11(4):361-370. doi: https://doi.org/10.1053/j.ackd.2004.07.009Coco M. In Reply: Fragility fractures in chronic kidney disease: A clarification of views. Cleve Clin J Med. 2010;77(2):75. doi: https://doi.org/10.3949/ccjm/77c:02004Coco M. In Reply: Fragility fractures in chronic kidney disease: A clarification of views. Cleve Clin J Med. 2010;77(2):75. doi: https://doi.org/10.3949/ccjm/77c:02004Zayour D, Daouk M, Medawar W, et al. Predictors of bone mineral density in patients on hemodialysis. Transplant Proc. 2004;36(5):1297-1301. doi: https://doi.org/10.1016/j.transproceed.2004.05.069Zayour D, Daouk M, Medawar W, et al. Predictors of bone mineral density in patients on hemodialysis. Transplant Proc. 2004;36(5):1297-1301. doi: https://doi.org/10.1016/j.transproceed.2004.05.069Alem AM, Sherrard DJ, Gillen DL, et al. Increased risk of hip fracture among patients with endstage renal disease. Kidney Int. 2000;58(1):396-399. doi: https://doi.org/10.1046/j.1523-1755.2000.00178.xAlem AM, Sherrard DJ, Gillen DL, et al. Increased risk of hip fracture among patients with endstage renal disease. Kidney Int. 2000;58(1):396-399. doi: https://doi.org/10.1046/j.1523-1755.2000.00178.xCoco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis. 2000;36(6):1115-1121. doi: https://doi.org/10.1053/ajkd.2000.19812Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis. 2000;36(6):1115-1121. doi: https://doi.org/10.1053/ajkd.2000.19812Fried LF, Biggs ML, Shlipak MG, et al. Association of Kidney Function with Incident Hip Fracture in Older Adults. J Am Soc Nephrol. 2007;18(1):282-286. doi: https://doi.org/10.1681/ASN.2006050546Fried LF, Biggs ML, Shlipak MG, et al. Association of Kidney Function with Incident Hip Fracture in Older Adults. J Am Soc Nephrol. 2007;18(1):282-286. doi: https://doi.org/10.1681/ASN.2006050546McNerny EMB, Nickolas TL. Bone Quality in Chronic Kidney Disease: Definitions and Diagnostics. Curr Osteoporos Rep. 2017;15(3):207-213. doi: https://doi.org/10.1007/s11914-017-0366-zMcNerny EMB, Nickolas TL. Bone Quality in Chronic Kidney Disease: Definitions and Diagnostics. Curr Osteoporos Rep. 2017;15(3):207-213. doi: https://doi.org/10.1007/s11914-017-0366-zDenburg MR, Kumar J, Jemielita T, et al. Fracture Burden and Risk Factors in Childhood CKD: Results from the CKiD Cohort Study. J Am Soc Nephrol. 2016;27(2):543-550. doi: https://doi.org/10.1681/ASN.2015020152Denburg MR, Kumar J, Jemielita T, et al. Fracture Burden and Risk Factors in Childhood CKD: Results from the CKiD Cohort Study. J Am Soc Nephrol. 2016;27(2):543-550. doi: https://doi.org/10.1681/ASN.2015020152McCloskey E V., Odén A, Harvey NC, et al. A Meta-Analysis of Trabecular Bone Score in Fracture Risk Prediction and Its Relationship to FRAX. J Bone Miner Res. 2016;31(5):940-948. doi: https://doi.org/10.1002/jbmr.2734McCloskey E V., Odén A, Harvey NC, et al. A Meta-Analysis of Trabecular Bone Score in Fracture Risk Prediction and Its Relationship to FRAX. J Bone Miner Res. 2016;31(5):940-948. doi: https://doi.org/10.1002/jbmr.2734Yong-man L, Hui-wen X, Kuo-huan L. The effects of calciumregulating-hormone on BMC in patients with CRF. J Tongji Med Univ. 1995;15(2):95-97. doi: https://doi.org/10.1007/BF02887910Yong-man L, Hui-wen X, Kuo-huan L. The effects of calciumregulating-hormone on BMC in patients with CRF. J Tongji Med Univ. 1995;15(2):95-97. doi: https://doi.org/10.1007/BF02887910Sampaio Lacativa PG, Carvalho de Mendonça LM, de Mattos Patrício Filho PJ, et al. Risk Factors for Decreased Total Body and Regional Bone Mineral Density in Hemodialysis Patients With Severe Secondary Hyperparathyroidism. J Clin Densitom. 2005;8(3):352-361. doi: https://doi.org/10.1385/JCD:8:3:352Sampaio Lacativa PG, Carvalho de Mendonça LM, de Mattos Patrício Filho PJ, et al. Risk Factors for Decreased Total Body and Regional Bone Mineral Density in Hemodialysis Patients With Severe Secondary Hyperparathyroidism. J Clin Densitom. 2005;8(3):352-361. doi: https://doi.org/10.1385/JCD:8:3:352Miller M, Chin J, Miller S, Fox J. Disparate effects of mild, moderate, and severe secondary hyperparathyroidism on cancellous and cortical bone in rats with chronic renal insufficiency. Bone. 1998;23(3):257-266. doi: https://doi.org/10.1016/S8756-3282(98)00098-2Miller M, Chin J, Miller S, Fox J. Disparate effects of mild, moderate, and severe secondary hyperparathyroidism on cancellous and cortical bone in rats with chronic renal insufficiency. Bone. 1998;23(3):257-266. doi: https://doi.org/10.1016/S8756-3282(98)00098-2Карлович Н.В., Мохорт Т.В. Вторичный гиперпаратиреоз при хронической болезни почек: монография. — Минск; 2021. 177 с.Karlovich NV, Mokhort TV. Secondary hyperparathyroidism in chronic kidney disease (monography). Minsk; 2021. 177 p. (In Russ.).Amrein K, Scherkl M, Hoffmann M, et al. Vitamin D deficiency 2.0: an update on the current status worldwide. Eur J Clin Nutr. 2020;74(11):1498-1513. doi: https://doi.org/10.1038/s41430-020-0558-yAmrein K, Scherkl M, Hoffmann M, et al. Vitamin D deficiency 2.0: an update on the current status worldwide. Eur J Clin Nutr. 2020;74(11):1498-1513. doi: https://doi.org/10.1038/s41430-020-0558-yBover J, Cozzolino M. Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin D receptor activation. Kidney Int Suppl. 2011;1(4):122-129. doi: https://doi.org/10.1038/kisup.2011.28Bover J, Cozzolino M. Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin D receptor activation. Kidney Int Suppl. 2011;1(4):122-129. doi: https://doi.org/10.1038/kisup.2011.28Карлович Н.В., Сазонова Е.Г., Валовик О.Э., и др. Опыт применения колекальциферола для коррекции дефицита витамина D и вторичного гиперпаратиреоза у пациентов с хронической болезнью почек // Лечебное дело. — 2019. — Т. 4. — №68. — С. 34-40.Karlovich NV, Sazonava EG, Valovik OE, et al. Experience of colecalciferol use for the correction of vitamin D deficiency and secondary hyperparathyroidism in patients with chronic kidney disease. Lechebnoe delo. 2019;4(68): 4-40. (In Russ.).Williams S., Malatesta K., Norris K. Vitamin D and chronic kidney disease. Ethn Dis. 2009;19(4 Suppl 5): S5-8-11.Williams S., Malatesta K., Norris K. Vitamin D and chronic kidney disease. Ethn Dis. 2009;19(4 Suppl 5): S5-8-11.Cunningham J, Sprague SM, Cannata-Andia J, et al. Osteoporosis Work Group. Osteoporosis in chronic kidney disease. Am J Kidney Dis. 2004;43(3):566-571. doi: https://doi.org/10.1053/j.ajkd.2003.12.004Cunningham J, Sprague SM, Cannata-Andia J, et al. Osteoporosis Work Group. Osteoporosis in chronic kidney disease. Am J Kidney Dis. 2004;43(3):566-571. doi: https://doi.org/10.1053/j.ajkd.2003.12.004Kraut J.A., Madias N.E. Lactic acidosis. N Engl J Med. 2015;372(11):1078-1079. doi: https://doi.org/10.1056/NEJMc1500327Kraut J.A., Madias N.E. Lactic acidosis. N Engl J Med. 2015;372(11):1078-1079. doi: https://doi.org/10.1056/NEJMc1500327Tao L, Xu H, Sun M, Ikeda T. Investigation of the bone mineral density in hemodialysis patients for different terms. Hunan Yi Ke Da Xue Xue Bao. 1999;24(2):177-178.Tao L, Xu H, Sun M, Ikeda T. Investigation of the bone mineral density in hemodialysis patients for different terms. Hunan Yi Ke Da Xue Xue Bao. 1999;24(2):177-178.Carrero JJ, Qureshi AR, Nakashima A, et al. Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease. Nephrol Dial Transplant. 2011;26(1):184-190. doi: https://doi.org/10.1093/ndt/gfq397Carrero JJ, Qureshi AR, Nakashima A, et al. Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease. Nephrol Dial Transplant. 2011;26(1):184-190. doi: https://doi.org/10.1093/ndt/gfq397Albrand G, Munoz F, Sornay-Rendu E, et al. Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: The OFELY Study. Bone. 2003;32(1):78-85. doi: https://doi.org/10.1016/S8756-3282(02)00919-5Albrand G, Munoz F, Sornay-Rendu E, et al. Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: The OFELY Study. Bone. 2003;32(1):78-85. doi: https://doi.org/10.1016/S8756-3282(02)00919-5Albaaj F, Sivalingham M, Haynes P, et al. Prevalence of hypogonadism in male patients with renal failure. Postgrad Med J. 2006;82(972):693-696. doi: https://doi.org/10.1136/pgmj.2006.045963Albaaj F, Sivalingham M, Haynes P, et al. Prevalence of hypogonadism in male patients with renal failure. Postgrad Med J. 2006;82(972):693-696. doi: https://doi.org/10.1136/pgmj.2006.045963Weisinger JR, Gonzalez L, Alvarez H, et al. Role of persistent amenorrhea in bone mineral metabolism of young hemodialyzed women. Kidney Int. 2000;58(1):331-335. doi: https://doi.org/10.1046/j.1523-1755.2000.00170.xWeisinger JR, Gonzalez L, Alvarez H, et al. Role of persistent amenorrhea in bone mineral metabolism of young hemodialyzed women. Kidney Int. 2000;58(1):331-335. doi: https://doi.org/10.1046/j.1523-1755.2000.00170.xNickolas TL, Cremers S, Zhang A, et al. Discriminants of Prevalent Fractures in Chronic Kidney Disease. J Am Soc Nephrol. 2011;22(8):1560-1572. doi: https://doi.org/10.1681/ASN.2010121275Nickolas TL, Cremers S, Zhang A, et al. Discriminants of Prevalent Fractures in Chronic Kidney Disease. J Am Soc Nephrol. 2011;22(8):1560-1572. doi: https://doi.org/10.1681/ASN.2010121275West SL, Jamal SA, Lok CE. Tests of neuromuscular function are associated with fractures in patients with chronic kidney disease. Nephrol Dial Transplant. 2012;27(6):2384-2388. doi: https://doi.org/10.1093/ndt/gfr620West SL, Jamal SA, Lok CE. Tests of neuromuscular function are associated with fractures in patients with chronic kidney disease. Nephrol Dial Transplant. 2012;27(6):2384-2388. doi: https://doi.org/10.1093/ndt/gfr620Fahal IH. Uraemic sarcopenia: aetiology and implications. Nephrol Dial Transplant. 2014;29(9):1655-1665. doi: https://doi.org/10.1093/ndt/gft070Fahal IH. Uraemic sarcopenia: aetiology and implications. Nephrol Dial Transplant. 2014;29(9):1655-1665. doi: https://doi.org/10.1093/ndt/gft070Jamal SA, West SL, Nickolas TL. The clinical utility of FRAX to discriminate fracture status in men and women with chronic kidney disease. Osteoporos Int. 2014;25(1):71-76. doi: https://doi.org/10.1007/s00198-013-2524-1Jamal SA, West SL, Nickolas TL. The clinical utility of FRAX to discriminate fracture status in men and women with chronic kidney disease. Osteoporos Int. 2014;25(1):71-76. doi: https://doi.org/10.1007/s00198-013-2524-1Kanis JA, McCloskey EV, Harvey NC, et al. Intervention Thresholds and the Diagnosis of Osteoporosis. J Bone Miner Res. 2015;30(10):1747-1753. doi: https://doi.org/10.1002/jbmr.2531Kanis JA, McCloskey EV, Harvey NC, et al. Intervention Thresholds and the Diagnosis of Osteoporosis. J Bone Miner Res. 2015;30(10):1747-1753. doi: https://doi.org/10.1002/jbmr.2531Lorentzon M, Branco J, Brandi ML, et al. Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis. Adv Ther. 2019;36(10):2811-2824. doi: https://doi.org/10.1007/s12325-019-01063-9Lorentzon M, Branco J, Brandi ML, et al. Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis. Adv Ther. 2019;36(10):2811-2824. doi: https://doi.org/10.1007/s12325-019-01063-9National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42 (4S3):S1-201National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42 (4S3):S1-201DeVita MV, Rasenas LL, Bansal M, et al. Assessment of renal osteodystrophy in hemodialysis patients. Medicine (Baltimore). 1992;71(5):284-290. doi: https://doi.org/10.1097/00005792-199209000-00003DeVita MV, Rasenas LL, Bansal M, et al. Assessment of renal osteodystrophy in hemodialysis patients. Medicine (Baltimore). 1992;71(5):284-290. doi: https://doi.org/10.1097/00005792-199209000-00003Baszko-Blaszyk D, Grzegorzewska AE, Horst-Sikorska W, Sowinski J. Bone mass in chronic renal insufficiency patients treated with continuous ambulatory peritoneal dialysis. Adv Perit Dial. 2001;17:109-113Baszko-Blaszyk D, Grzegorzewska AE, Horst-Sikorska W, Sowinski J. Bone mass in chronic renal insufficiency patients treated with continuous ambulatory peritoneal dialysis. Adv Perit Dial. 2001;17:109-113Bakr AM. Bone mineral density and bone turnover markers in children with chronic renal failure. Pediatr Nephrol. 2004;19(12):1390-1393. doi: https://doi.org/10.1007/s00467-004-1670-2Bakr AM. Bone mineral density and bone turnover markers in children with chronic renal failure. Pediatr Nephrol. 2004;19(12):1390-1393. doi: https://doi.org/10.1007/s00467-004-1670-2Salem N, Bakr A. Size-adjustment techniques of lumbar spine dual energy X-ray absorptiometry measurements in assessing bone mineralization in children on maintenance hemodialysis. J Pediatr Endocrinol Metab. 2021;34(10):1291-1302. doi: https://doi.org/10.1515/jpem-2021-0081Salem N, Bakr A. Size-adjustment techniques of lumbar spine dual energy X-ray absorptiometry measurements in assessing bone mineralization in children on maintenance hemodialysis. J Pediatr Endocrinol Metab. 2021;34(10):1291-1302. doi: https://doi.org/10.1515/jpem-2021-0081Negri AL, Barone R, Quiroga MA, et al. Bone Mineral Density: Serum Markers of Bone Turnover and Their Relationships in Peritoneal Dialysis. Perit Dial Int J Int Soc Perit Dial. 2004;24(2):163-168. doi: https://doi.org/10.1177/089686080402400207Negri AL, Barone R, Quiroga MA, et al. Bone Mineral Density: Serum Markers of Bone Turnover and Their Relationships in Peritoneal Dialysis. Perit Dial Int J Int Soc Perit Dial. 2004;24(2):163-168. doi: https://doi.org/10.1177/089686080402400207Yamaguchi T, Sugimoto T. Update on fracture risk in life style-related disease. Clin Calcium. 2014;24(3):349-355. doi: https://doi.org/CliCa1403349355Yamaguchi T, Sugimoto T. Update on fracture risk in life style-related disease. Clin Calcium. 2014;24(3):349-355. doi: https://doi.org/CliCa1403349355Naylor KL, Leslie WD, Hodsman AB, et al. FRAX Predicts Fracture Risk in Kidney Transplant Recipients. Transplantation. 2014;97(9):940-945. doi: https://doi.org/10.1097/01. TP.0000438200.84154.1aNaylor KL, Leslie WD, Hodsman AB, et al. FRAX Predicts Fracture Risk in Kidney Transplant Recipients. Transplantation. 2014;97(9):940-945. doi: https://doi.org/10.1097/01. TP.0000438200.84154.1aHounkpatin HO, Harris S, Fraser SDS, et al. Prevalence of chronic kidney disease in adults in England: comparison of nationally representative cross-sectional surveys from 2003 to 2016. BMJ Open. 2020;10(8):e038423. doi: https://doi.org/10.1136/bmjopen-2020-038423Hounkpatin HO, Harris S, Fraser SDS, et al. Prevalence of chronic kidney disease in adults in England: comparison of nationally representative cross-sectional surveys from 2003 to 2016. BMJ Open. 2020;10(8):e038423. doi: https://doi.org/10.1136/bmjopen-2020-038423Tartaglione L, Pasquali M, Rotondi S, et al. Positioning novel biologicals in CKD-mineral and bone disorders. J Nephrol. 2017;30(5):689-699. doi: https://doi.org/10.1007/s40620-017-0410-1Tartaglione L, Pasquali M, Rotondi S, et al. Positioning novel biologicals in CKD-mineral and bone disorders. J Nephrol. 2017;30(5):689-699. doi: https://doi.org/10.1007/s40620-017-0410-1Nakashima A, Yorioka N, Mizutani T, et al. Serum Cross-Linked N-Terminal Telopeptide of Type I Collagen for Evaluation of Renal Osteodystrophy in Hemodialysis Patients. Nephron Clin Pract. 2005;99(3):78-85. doi: https://doi.org/10.1159/000083418Nakashima A, Yorioka N, Mizutani T, et al. Serum Cross-Linked N-Terminal Telopeptide of Type I Collagen for Evaluation of Renal Osteodystrophy in Hemodialysis Patients. Nephron Clin Pract. 2005;99(3):78-85. doi: https://doi.org/10.1159/000083418Ishimura E, Okuno S, Ichii M, et al. Relationship between serum sclerostin, bone metabolism markers, and bone mineral density in maintenance hemodialysis patients. J Clin Endocrinol Metab. 2014;99(11):4315-4320. doi: https://doi.org/10.1210/jc.2014-2372Ishimura E, Okuno S, Ichii M, et al. Relationship between serum sclerostin, bone metabolism markers, and bone mineral density in maintenance hemodialysis patients. J Clin Endocrinol Metab. 2014;99(11):4315-4320. doi: https://doi.org/10.1210/jc.2014-2372Cejka D. Cardiovascular Safety of Anti-Sclerostin Therapy in Chronic Kidney Disease. Metabolites. 2021;11(11):770. doi: https://doi.org/10.3390/metabo11110770Cejka D. Cardiovascular Safety of Anti-Sclerostin Therapy in Chronic Kidney Disease. Metabolites. 2021;11(11):770. doi: https://doi.org/10.3390/metabo11110770Карлович Н.В., Спиридонова О.С., Сазонова Е.Г., Мохорт Т.В. Определение референтного интервала паратгормона у пациентов с различными стадиями хронической болезни почек // Весці Нацыянальнай акадэміі навук Беларусі. Серыя медыцынскіх навук. — 2020. — Т. 19. — №2. — C. 186-194. doi: https://doi.org/10.29235/1814-6023-2021-18-2-186-195Karlovich NV, Spiridonova OS, Sazonava EG, Mokhort TV. Determination of parathyroid hormone reference interval in patients with various stages of chronic kidney disease. Vesti of National Academy of Sciences of Belarus. Medical sciences. 2020;19(2):186-194. (In Russ.). doi: https://doi.org/10.29235/1814-6023-2021-18-2-186-195

The authors declare that there are no conflicts of interest present.